布地奈德福莫特罗干粉吸入剂对中重度持续性哮喘的疗效观察

Effect of inhaled dry-powder budesonide/fomoterol on moderate to severe persistent asthma

目的:评估布地奈得福莫特罗干粉吸入剂治疗中重度持续性哮喘的临床疗效和耐受性。方法:采用自身对照研究方法,39例患者吸入布地奈得福莫特罗干粉吸入剂(160μg/4.5μg)每日2次,每次1吸,持续3个月,每个月复诊1次,观察临床症状(日间症状评分、夜间症状评分、全天无症状天数、速效β2受体激动剂使用次数的变化等)、肺功能(FEV1、PEF)变化和不良事件发生情况。结果:患者治疗后1、2、3个月FEV1、PEF明显增加。日间症状评分、夜间症状评分、速效!2受体激动剂使用次数显著减少,全天无症状天数明显增加(P<0.001)。仅有1例患者出现声音嘶哑。结论:布地奈得福莫特罗干粉吸入剂对于中重度持续性哮喘患者具有良好的疗效和安全性。

Objective To evaluate clinical efficacy and safety of inhaled dry-powder budesonide/fomoterol in the treatment of patients with moderate to severe persistent asthma. Methods This was an opened own control study. 39 patients with moderate to severe asthma were given budesonide/fomoterol 160 μg/4.5 μg inhalation twice daily via turbuhaler for 3 months. Clinical symptoms,lung function and adverse events were observed. The peak expiratory flow （PEF）, forced expiratory volume in one second（FEV1）, morning and evening asthma symptom scores, symptomless time and the amount of use of inhaled short-acting 132-adrenoceptor agonist bronchodilators were detected. Results The treatment with budesonide/fomoterol turbulaler resulted in remarkably improvement in morning and evening asthma symptom scores,and FEV1 and PEF were notably increased after 1 month of treatment and during the treatment period （P〈 0.01）, At the end of 3 months treatment,the amount of a symptomless day of patients were increased and the amount of use of inhaled short-acting β2-adrenoeeptor agonist bronehodilators was notably reduced （P 〈 0,001 ）. There were only 1 patient had hoarseness. Conclusion budesonide/fomoterol turbulaler possesses the advantage of effectiveness, safety and well tolerance in treatment of patients with moderate to severe asthma.